TIME TO MARKET AND PRICE COMPARISON FOR BIOSIMILAR DRUGS IN EU5


López-Martínez N¹, Prada M², Berard I³, Schleich W⁴, Melson C⁵


¹Oblikue Consulting, Barcelona, Spain; ²Intexo SrI, Milan, Italy; ³Nextep, Paris, France; ⁴MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany; ⁵Decideum, London, UK.

INTRODUCTION

- After a medicine receives European Medicines Agency (EMA) marketing authorization, each member state then decides how that medicine is implemented at local level. In Germany, after EMA marketing authorization the drug is available by law. The existing differences between European countries in their policies on biosimilars may explain the heterogeneity in the drug uptake of these biosimilars. As a consequence of these differences, variations in savings can also be observed¹.
- The aim of this study was to compare the time elapsed from EMA authorisation to national commercialization. Additionally, price differences of biosimilar drugs in five European countries (EU5) were assessed to evaluate whether the existing biosimilar policies might drive this difference.

Figure 1. Biosimilars commercialized in the EU5 countries










METHODS

- Countries included in the analysis were: United Kingdom (UK), Germany, France, Italy and Spain (EU5).
- Authorized biosimilar drugs from April-2006 to January-2018 were extracted from the official EMA's website².
- For each country the commercialization of these biosimilars was confirmed via the official websites of the considered National Health Authorities (Agenzia Italiana del Farmaco -AIFA, Agence Nationale de Sécurité du Médicament - ANSM, Gemeinsamer Bundesausschuss – G-BA, Medicines and Health Products Regulatory Agency – MHRA and Agencia Española de Medicamentos y Productos Sanitarios - AEMPS and Consejo General de Colegios Oficiales de Farmacéuticos - CGCOF)³⁻⁹ in May 2018.
- National commercialization dates in each country were collected through the official sources which was the basis for the calculation of median time differences between the EMA authorization and national commercialization date.
- In addition to the median time between EMA approval and national commercialization, the range considering the minimum and maximum time period observed for the different biosimilars evaluated was also calculated.
- Variations in drug prices between the EU5 were also assessed after consulting countryspecific official sources^{4,8,10-13}. For price comparisons, ex-factory prices were considered (May 2018 €). For Italy and Spain any mandatory low discount has been considered.
- For the price comparison, the package which was available in all EU5 countries was chosen in order to guarantee comparability.

- 36% (n=14) of the authorized biosimilars have been launched in all EU5 countries. Of those, the commercialization date was available for only 9 biosimilars: Abasaglar[®], Accofil[®], Benepali[®], Erelzi[®], Flixabi[®], Inflectra[®], Ovaleap[®], Remsima[®] and Truxima[®].
- Of these 9 biosimilars with an available commercialization date in all EU5 countries, the median time elapsed from EMA authorisation to national commercialization was 4.5 months (range 0.1-27.4) in the UK; 5.9 months (range 0.7-25.2) in Germany; 8.6 months (range 4.3-26.7) in Spain; 13.5 months (range 5.4-31.7) in France and 15.3 months (range 6.5-35.1) in Italy.

Figure 2. Time (months) from EMA authorisation to national commercialization across EU5



Considerable variations on the median price were observed for some of the biosimilars

RESULTS

- 39 biosimilars for 15 active substances were authorized by the EMA between April 2006 and January 2018 (Table 1).
- Around 67% (n=26) of the total biosimilars authorized have been commercialized in at least one EU5 country. The overall percentage of commercialized biosimilars ranged from 44% in both UK and Spain to 62% in Germany – in Italy and France the figures were 49% and 51% respectively. In some cases, the existing patents were the reason for the lack of commercialization (i.e. bevacizumab)¹⁴.


Table 1. Biosimilars and their corresponding active substances authorized by the EMA between April 2006 and January 2018

Active substances	Biosimilar brand names	EMA authorization
	Amgevita [®]	22/03/2017
🔹 adalimumah	 Solymbic[®] 	22/03/2017
 adalimumab 	Imraldi [®]	24/08/2017
	Cyltezo [®]	10/11/2017
bevacizumab	 Mvasi[®] 	15/01/2018
enoxaparin sodium	Inhixa [®]	15/09/2016
	Thorinane [®]	15/09/2016
	Abseamed [®]	28/08/2007
 epoetin alfa 	 Binocrit[®] 	28/08/2007
	Epoetin Alfa Hexal [®]	28/08/2007
 epoetin zeta 	Retacrit [®]	18/12/2007
	 Silapo[®] 	18/12/2007
etanercept	 Benepali[®] 	14/01/2016
	Erelzi [®]	23/06/2017
	Ratiograstim [®]	15/09/2008
	Tevagrastim [®]	15/09/2008
	 Filgrastim Hexal[®] 	06/02/2009
filgrastim	Zarzio [®]	06/02/2009
	Nivestim [®]	08/06/2010
	 Grastofil[®] 	18/10/2013
	Accofil [®]	18/09/2014
follitropin alfa	 Ovaleap[®] 	27/09/2013
	Bemfola [®]	27/03/2014
	Inflectra [®]	10/09/2013
infliximab	Remsima [®]	10/09/2013
	Flixabi [®]	26/05/2016
insulin glargine	 Abasaglar[®] (previously Abasria)[®] 	09/09/2014
	Lusduna [®]	04/01/2017
insulin lispro	Insulin lispro Sanofi [®]	19/07/2017
 rituximab 	Truxima [®]	17/02/2017
	Rixathon [®]	15/06/2017
	Riximyo [®]	15/06/2017
	 Blitzima[®] 	13/07/2017
	 Ritemvia[®] 	13/07/2017
	 Rituzena[®] (previously Tuxella)[®] 	13/07/2017
somatropin	 Omnitrope[®] 	12/04/2006
teriparatide	 Terrosa[®] 	04/01/2017
	 Movymia[®] 	11/01/2017
trastuzumab	 Ontruzant[®] 	15/11/2017

launched in all EU5 countries. For the majority of biosimilars evaluated, and considering the median price observed in the five countries, variations ±25% were observed (Figure 3).

 \geq In some countries, the price of Erelzi[®], is 68% higher than the EU5 median price, for instance.

Figure 3. Minimum and maximum price variations over the median price observed across EU5



Price information for Accofil[®] is not shown since the available packs could not be compared and the comparison has been made based on the price per mg.

CONCLUSIONS

- Biosimilar policies may influence the time to availability of these usually cheaper drugs. Moreover, these policies may impact the prices of biosimilars. For instance,
- through mandatory price discounts (i.e. in France a mandatory 30% discount vs. the original drug price) or via the competition (i.e. confidential contracting options in Germany).
- The joint analysis of the EU5 countries is important in order to understand the differences in market access processes between countries and thus to implement strategies accordingly.
- The analysis has considered the EU5 national regulatory systems and variability in access and prices of approved biosimilars in different EU5 countries has been found.

REFERENCES

1.	Moorkens E, et al. PLoS One. 2017;12(12):e0190147. 9. Agencia Española de Medicamentos y Productos Sanitarios.
2.	European Medicines Agency. [Accessed June 2018]. Available at: [Accessed June 2018]. Available at:
	http://www.ema.europa.eu/
3.	Gazzetta Ufficiale Repubblica Italiana [Online]. Available at:10. AIFA official website. Tabelle Farmaci Classe A e H [Online].
	http://www.gazzettaufficiale.it [Accessed 1st June 2018]. Available at: http://www.aifa.gov.it/content/tabelle-farmaci-di-classe-
4.	Legifrance website. French Official Journal [Online]. Available at: e-h-al-15052018 [Accessed 22nd June 2018].
	https://www.legifrance.gouv.fr/ [Accessed 1st June 2018]. 11. Lauer-Fischer GmbH. Lauer-Taxe® [Online]. Available at:
5.	Agence Nationale de Sécurité du Médicament [Online]. Available at: https://www.cgm.com/lauer-fischer/index.de.jsp [Accessed 1st June
	https://ansm.sante.fr/ [Accessed 1st June 2018]. 2018].
6.	Federal Joint-Committee – Gemeinsamer Bundesausschus [Online].12. MIMS [Online]. Available at: https://www.mims.co.uk/drugs
	Available at: https://www.g-ba.de/informationen/nutzenbewertung/ [Accessed 1st June 2018].
	[Accessed 1st June 2018]. 13. Ministerio de Sanidad, Consumo y Bienestar Social [Online].
7.	National Institute for Health and Care Excellence [Online]. Available Available at:
	at: https://www.nice.org.uk [Accessed 1st June 2018]. https://www.mscbs.gob.es/profesionales/farmacia/pdf/Deducciones
8.	Consejo General de Colegios Oficiales de Farmacéuticos. Bot- Mayo18.pdf [Accessed October 2010].
	PLUS Portal Farma [Online]. Available at:14. Serna-Gallegos TR, et al. Recent Pat Biotechnol. 2018;12(2):101-
	https://botplusweb.portalfarma.com/ [Accessed 1st June 2018]. 12.

ISPOR 21st Annual European Congress. 10-14 November 2018. Barcelona, Spain.









